NRX Pharmaceuticals, Inc. (NRXP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, NRX Pharmaceuticals reported revenue of $1.2M. Net income was -$28.6M (a -2336.5% net margin). Gross margin was 58.8% and operating margin was -1324.4%. Operating activities generated -$14.1M of cash, leaving -$14.1M of free cash flow. At fiscal year end, NRX Pharmaceuticals held $13.0M in total assets against $28.9M in total liabilities, including $7.8M of cash and equivalents.
Open the full interactive NRX Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
NRX Pharmaceuticals Key Stats
| Share Price | $2.70 |
|---|---|
| Market Cap | $101.7M |
| 52-Week Range | $1.68 – $4.62 |
| Shares Outstanding | 37.6 million (basic, 2026 Q2) |
NRX Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.2M |
| Cost of Goods Sold | — | — | — | — | — | $17.4M |
| Gross Profit | — | — | — | — | — | $720,000 |
| Operating Income | -$907,406 | -$115.8M | -$44.3M | -$27.8M | -$18.5M | -$16.2M |
| Pre-Tax Income | -$416,571 | -$93.1M | -$39.8M | -$30.1M | -$25.1M | -$28.6M |
| Income Tax | $17,841 | — | — | — | $0 | $0 |
| Net Income | -$434,412 | -$93.1M | -$39.8M | -$30.1M | -$25.1M | -$28.6M |
| Diluted EPS | -$1.59 | -$19.80 | -$6.00 | — | — | — |
NRX Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $242,000 | $983,000 | $1.1M | $1.1M |
| Net Income | -$5.9M | $361,000 | -$1.4M | -$16.5M |
NRX Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $20.1M | $4.6M | $1.4M | $7.8M |
| Current Assets | $82,458 | $32.7M | $25.8M | $6.9M | $3.3M | $8.9M |
| Total Assets | $6.1M | $32.7M | $25.8M | $7.3M | $3.7M | $13.0M |
| Current Liabilities | — | $11.9M | $15.6M | $19.0M | $21.9M | $28.6M |
| Total Long-Term Debt | — | — | — | $18.3M | $6.3M | — |
| Total Liabilities | $3.3M | $11.9M | $18.4M | $19.0M | $26.9M | $28.9M |
| Shareholders' Equity | $2.8M | $20.8M | $7.4M | -$11.7M | -$23.2M | -$15.9M |
NRX Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$598,617 | -$37.7M | -$39.8M | -$21.7M | -$10.6M | -$14.1M |
| Cash From Investing | $26.2M | -$7,000 | -$10,000 | -$3,000 | $0 | -$2.8M |
| Cash From Financing | -$25.6M | $63.5M | $32.2M | $6.2M | $7.5M | $23.3M |
| Free Cash Flow | — | -$37.7M | -$39.8M | -$21.7M | -$10.6M | -$14.1M |
Figures from NRX Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full NRX Pharmaceuticals financials page for every line item.
NRX Pharmaceuticals Company Profile
| Ticker | NRXP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Wilmington, Delaware |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001719406 |
Frequently Asked Questions
What was NRX Pharmaceuticals' revenue in fiscal 2025?
NRX Pharmaceuticals (NRXP) reported revenue of $1.2M for fiscal 2025.
What is NRX Pharmaceuticals' annual revenue history?
NRX Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $1.2M.
What was NRX Pharmaceuticals' net income in fiscal 2025?
NRX Pharmaceuticals reported net income of -$28.6M for fiscal 2025.
How much free cash flow did NRX Pharmaceuticals generate in fiscal 2025?
NRX Pharmaceuticals generated -$14.1M of free cash flow in fiscal 2025.
What was NRX Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), NRX Pharmaceuticals reported revenue of $1.1M.
How many shares of NRX Pharmaceuticals are outstanding?
NRX Pharmaceuticals reported a weighted average of 37.6 million basic shares outstanding in 2026 Q2.
What is NRX Pharmaceuticals' market cap?
Based on its latest closing price, NRX Pharmaceuticals (NRXP) has a market capitalization of about $101.7M.
When does NRX Pharmaceuticals' fiscal year end?
NRX Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is NRX Pharmaceuticals headquartered?
NRX Pharmaceuticals lists its business address in Wilmington, Delaware in its SEC filings.